Company profile for Arnatar Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Arnatar Therapeutics is a clinical-stage biotechnology company based in San Diego, pioneering a dual-modality RNA platform to address severe and underserved diseases. Leveraging its proprietary DARGER™ platform, Arnatar develops both gene-silencing siRNA therapeutics and first-in-class antisense oligonucleotides (ASOs) that upregulate protein expression. This innovative approach enables the company to target previously untre...
Arnatar Therapeutics is a clinical-stage biotechnology company based in San Diego, pioneering a dual-modality RNA platform to address severe and underserved diseases. Leveraging its proprietary DARGER™ platform, Arnatar develops both gene-silencing siRNA therapeutics and first-in-class antisense oligonucleotides (ASOs) that upregulate protein expression. This innovative approach enables the company to target previously untreatable conditions across cardiometabolic, liver, central nervous system (CNS), and kidney diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
10355 Science Center Drive Suite 130 San Diego, CA 92121
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/20/3169276/0/en/Arnatar-Therapeutics-Announces-Upcoming-Presentations-at-AASLD-The-Liver-Meeting-2025-and-ASN-Kidney-Week-2025.html

GLOBENEWSWIRE
20 Oct 2025

https://www.globenewswire.com/news-release/2025/08/25/3138381/0/en/Arnatar-Therapeutics-Emerges-from-Stealth-and-Announces-Receipt-of-FDA-Orphan-Drug-and-Rare-Pediatric-Disease-Designations-for-ART4.html

GLOBENEWSWIRE
25 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty